Malaria vaccines.
The development of an effective malaria vaccine is a feasible goal. Most of the vaccines being developed today are subunit vaccines derived from selected parasite antigens or their immunologically active fragments. The precise characterization of protective immune responses against Plasmodium parasites remains a fundamental part of present research aimed at obtaining a malaria vaccine(s).
Romero
P
P
Ludwig Institute for Cancer Research, Lausanne, Switzerland.
D000595:Amino Acid Sequence; D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D006801:Humans; D016778:Malaria, Falciparum / Q000517:prevention & control; D020066:Merozoite Surface Protein 1; D008969:Molecular Sequence Data; D010963:Plasmodium falciparum / Q000276:immunology*; D011498:Protein Precursors / Q000276:immunology; D015800:Protozoan Proteins / Q000276:immunology; D016052:Protozoan Vaccines; D014614:Vaccines, Synthetic / Q000276:immunology*
D000953:Antigens, Protozoan; D000954:Antigens, Surface; D020066:Merozoite Surface Protein 1; D011498:Protein Precursors; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D014614:Vaccines, Synthetic; C064783:sexual stage specific protein, Plasmodium